HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Preliminary report of Iranian Registry of Alzheimer's disease in Tehran province: A cross-sectional study in Iran.

AbstractBackground and Aims:
Alzheimer's disease (AD) is the main cause of dementia and over the 55 million people live with dementia worldwide. We aimed to establish the first database called the Iranian Alzheimer's Disease Registry to create a powerful source for future research in the country. In this report, the design and early results of the Iranian Alzheimer's Disease Registry will be described.
Methods:
We performed this multicenter investigation and patients' data including age, sex, educational level, disease status, Mini-Mental State Examination (MMSE), and Geriatric Depression Scale (GDS) from 2018 to 2021 were collected, registered, and analyzed by GraphPad Prism software.
Results:
Totally 200 AD patients were registered in our database. 107 (54%) were women and age of 147 (74%) were over 65. The mean age for men and women was 76.20 ± 8.29 and 76.40 ± 8.83 years, respectively. 132 (66%) were married and 64 (32%) were illiterate. Also, 94 (47%) were in the moderate stage of disease, and 150 (75%) lived at home together with their families. The most frequent neurological comorbidity was psychosis (n = 72, 36%), while hypertension was the most common non-neurological comorbidity (n = 104, 52%). The GDS score of women in the mild stage (5.23 ± 2.9 vs. 6.9 ± 2.6, p = 0.005) and moderate stage (5.36 ± 2.4 vs. 8.21 ± 2.06, p = <0.001) of the disease was significantly greater than men. In univariate analysis, MMSC score was remarkably associated with stroke (β = -2.25, p = 0.03), psychosis (β = -2.18, p = 0.009), diabetes (β = 3.6, p = <0.001), and hypercholesteremia (β = 1.67, p = 0.05). Also, the MMSE score showed a notable relationship with stroke (β = -2.13, p = 0.05) and diabetes (β = 3.26, p = <0.001) in multivariate analysis.
Conclusion:
Iranian Alzheimer's Disease Registry can provide epidemiological and clinical data to use for purposes such as enhancing the current AD management in clinical centers, filling the gaps in preventative care, and establishing effective monitoring and cure for the disease.
AuthorsJavad Fahanik-Babaei, Mohsen Sedighi, Soraya Mehrabi, Omid Pournik, Abbas Sheikh Taheri, Leila Kamalzadeh, Mahsa Zarei, Mehrdad Roghani, Fereshteh Golab, Mostafa Almasi, Afshin Etezadi, Siamak Afshin-Majd, Seyed Kazem Malakouti, Majid Rajabi, Mehdi Moghaddasi, Gholamreza Hajati, Fatemeh Golmohammadi Khamne, Arzhang Jafari, Alireza Amanollahi, Tourandokht Baluchnejadmojarad
JournalHealth science reports (Health Sci Rep) Vol. 5 Issue 6 Pg. e952 (Nov 2022) ISSN: 2398-8835 [Electronic] United States
PMID36439037 (Publication Type: Journal Article)
Copyright© 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: